Spinner, S
Crispatzu, G
Yi, J-H
Munkhbaatar, E
Mayer, P
Höckendorf, U
Müller, N
Li, Z
Schader, T
Bendz, H
Hartmann, S
Yabal, M
Pechloff, K
Heikenwalder, M
Kelly, G L
Strasser, A
Peschel, C
Hansmann, M-L
Ruland, J
Keller, U
Newrzela, S
Herling, M
Jost, P J
Article History
Received: 21 July 2015
Revised: 19 December 2015
Accepted: 25 January 2016
First Online: 8 March 2016
Competing interests
: GLK and AS work at the Walter and Eliza Hall Institute. This Institute receives milestone payments from Genentech Inc. and AbbVie for the development of BH3 mimetic drugs for cancer therapy. All the other authors declare no conflict of interest.